ANVISA registration, and why you cannot hold it yourself

For a large class of products, the gate into Brazil is not INMETRO but ANVISA — the health regulator that governs cosmetics, personal-hygiene goods, medical devices, food, dietary supplements, sanitising products and pharmaceuticals. If your product is applied to the body, ingested, or used in a clinical setting, assume ANVISA clearance is mandatory before a single unit clears customs. And the first thing to understand is structural: a foreign manufacturer cannot hold an ANVISA approval. It must be held by a Brazilian legal entity that carries an Autorização de Funcionamento (AFE), the operating licence ANVISA issues to companies importing and distributing regulated goods.

How heavy the approval is depends on risk. ANVISA runs a two-tier system. Lower-risk goods take the lighter path — cosmetics classed as Grade 1, or medical devices in Classes I and II, clear through a notification or cadastro, essentially a documentary registration that can be resolved in weeks. Higher-risk goods take the heavier path — Grade 2 cosmetics (those making functional claims, or for children, or with bleaching or anti-dandruff action) require full registration, typically around 120 days of technical analysis; Class III and IV devices require a registro with clinical, biocompatibility and sterilisation evidence, and realistically run twelve to eighteen months. Knowing which bucket you fall into before you plan a launch is the difference between a quarter and a year and a half.

For higher-risk manufacturing there is a second layer: the CBPF, Brazil's Good Manufacturing Practice certificate, which for pharmaceuticals and higher-class devices means your plant is inspected — or accepted via an equivalent such as MDSAP — and re-certified roughly every two years. Whatever the class, the foreign manufacturer's own paperwork is finite and familiar: a Letter of Authorization naming the Brazilian holder as your representative, and a Free Sale Certificate proving the product is legally sold in its home market. The manufacturer supplies the dossier; the Brazilian holder files it and owns the resulting registration number.

And that is the quiet trap, the same one INMETRO sets on the technical side. If the entity holding your ANVISA registration is your importer or distributor, they hold your market. Should the relationship end, you may not simply move the product to a new partner — the registration is theirs, and re-registering under a new holder can mean repeating much of the process. The defensive move is to decide, before signing, that the holder is either your own Brazilian entity or a neutral regulatory-only partner whose sole job is to hold registrations, not to sell your product.

One fresh wrinkle worth flagging: since April 2026, ANVISA-regulated imports must move through the DUIMP single import declaration on the Portal Único, with a product catalogue of technical attributes built before goods ship and an ANVISA import-purpose field that has been a hard validation since late May. It is an administrative change, not a new barrier, but mismatched data now stops containers rather than merely delaying paperwork. If you are weighing a Brazilian launch and are not sure which ANVISA path your product triggers — or who ought to hold the registration — a short Opportunity Scan maps the route before you commit to a partner who might otherwise end up holding it for you.